Iradimed Reports Record Q3 2026 Revenue Driven by New 3870 Pump Launch
Iradimed Corporation (IRMD) reported record third-quarter revenue of $24.2 million, marking a 14% year-over-year increase and an 18% sequential rise from Q2 2026. The growth was primarily fueled by the successful market launch and production ramp of the new 3870 MR IV pump platform, which saw over 400 systems produced during the quarter. Gross margins improved to 76% due to manufacturing efficiencies realized on this new platform. The company is seeing strong adoption of its quad stack configuration, with 70% of replacement orders converting to the higher-capacity setup. While management tightened full-year revenue guidance to $91.7 million–$93.2 million due to production constraints, they provided an optimistic outlook for 2027 with projected growth of 15% to 17%. The company maintains a strong liquidity position with $63.3 million in cash and cash equivalents.
Tickers: $IRMD
Topics: eps gross margin guidance product launch revenue growth